ARKUSDT
Ark / Tether USD
crypto Composite

Cathy Wood of ARK bought a bunch of shares today.

The age of FAANG is over. The age of CLAW has begun!
CLAW- Chronically Losing All Wealth
* C- Clover Health
* L- Lucid Group
* A- ARK Innovation ETF
* W- WeWork

Fellow Redditors, this could be the last opportunity to get into DRTS at these price levels.
For years this stock had only us retail, and even that barely, but now everything is lining up and coming together for institutions to start buying.
Just this week we learned that:
\- ARK has Bought 280,822 Shares
\- Daytona Street Capital Bought 151,227 Shares
\- Apella Capital Bought 382,284 Shares
\- Mariner added and now holds 123,250 Shares
Why now?
The company with the revolutionary cancer treatment that could treat every solid tumor even the most high unmet needs cancers like Pancreas and GBM, shared new data and results from their recent trials, proving to be both safe and effective against the dozens of tumor types tested.
DRTS is also expecting PMDA approval in Japan any day, which is validating and de-risking as the PMDA is considering the most rigorous approval to get. This will turn them from a pre-revenue & clinical-stage company into a potential commercial industry leader. If that wasn’t enough they also announced they started submitting the Phase 3 data to the FDA to start reviewing.
And the good news and speculation aren’t going unnoticed, they are showing up as increasing volume and growing market cap, crossing 500M not too long ago, which is another milestone funds are looking at as a sign to invest.
There’s so much more to get excited about, for example the new data showing immune system activation and training, but what might be most important is understanding how the institutional money works, because once they decide it’s a good investment, once the first funds start buying (as is happening with DRTS now), it’s a copy cat game, like dominoes, they all follow.
As always of course NFA and DYOR, but with the Clinical and Regulatory momentum, and a strong cash position that will only let funds in through the market, don’t let the institutions make their move before you.

Worth taking a look at DRTS, institutions started buying in this week, including:
- ARK 280,822 Shares
- Daytona Street Capital 151,227 Shares
- Apella Capital 382,284 Shares
- Mariner added and now holds 123,250 Shares
Expecting the PMDA approval and the FDA already reviewing Phase 3 trials, they join the high insider ownership and increased retail attention, along with the other funds buying, as the volume and market cap keep growing

thank you for reminding me of my investments in all the ARK stocks in 2021 (all sold at a loss so I could get into a Bogleheads method since). The memories!

I see the appeal with CRSP, especially with ARK's stake. Just keep an eye on their cash burn rate—fundamentals could shift quickly if market conditions change. Timing your entry will definitely be key here.

CRISPR Therapeutics (CRSP): Massive Insider Buying 6 Months Ago + ARK Owns 10% — Still Crisp, Still Risky 🧬

ARK Private Innovation ELTIF

I follow Kathy Wood's ARK investing closely. Rather than pick the next winners, I invest capital in some of her ETFs. She had incredible returns last year and her 3 year returns are great.

Sick AI reply!
You seem to only post about XOVR or the ARK venture fund. Also, are you 28 or 35? Your many posts on the topic seem to disagree.